Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02279823
Other study ID # 171-7152-201
Secondary ID
Status Completed
Phase Phase 2
First received October 7, 2014
Last updated March 9, 2017
Start date October 2014
Est. completion date May 2016

Study information

Verified date March 2017
Source Intrepid Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 95
Est. completion date May 2016
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Subject has mild to moderate androgenetic alopecia (AGA) in temple and vertex region

- Subject is willing to maintain the same hairstyle, hair length, and hair color throughout the study

- Subject agrees to continue his other general hair care products and regimen for the entire study

- Subjects who are sexually active with a female partner must be surgically sterile or agree to use an effective method of birth control from the first administration of the test article until 30 days after the last administration

Exclusion Criteria:

- Subject has any dermatological disorders of the scalp in the target region with the possibility of interfering with the application of the test article or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars, or scalp atrophy

- Subject has any condition in the opinion of the investigator that could interfere with the evaluation of the test articles or requires the use of interfering topical or systemic therapy (e.g., uncontrolled thyroid disease, certain genetic disorders that involve hair growth or patterns)

- Subject has a current or recent history (within 3 months) of hair transplants, hair weaves or non-breathable wigs and hair bonding

- Subject has a current or recent history (within 3 months) of active hair loss due to diffuse telogen effluvium, alopecia areata, scarring alopecia, trichotillomania or conditions/diseases other than AGA

- Subject has a current or recent history (within 3 months) of severe dietary changes or presenting a history of eating disorder(s)

- Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study

- Subject is currently enrolled in an investigational drug or device study

- Subject has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment

- Subject is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function

- Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits

- The subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles or tattoo ink

- Subject has used any of the following topical preparations or procedures on the scalp:

- Topical treatments including corticosteroids, pimecrolimus, tacrolimus, minoxidil, hormone therapy, anti-androgens or other agents that are known to affect hair growth in the opinion of the investigator within 12 weeks of the initiation of treatment

- Topical over-the-counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., brands such as Aminexil, Maxilene, Nioxin, Foltene, etc. or hair health or hair growth products with saw palmetto, copper, etc.) in the opinion of the investigator within 4 weeks of the initiation of treatment.

- Scalp procedures (surgical, laser, light or energy treatments, etc.) within 6 months of the initiation of treatment

- Subject has used the following systemic medications or procedures:

- Beta blockers, cimetidine, diazoxide, isotretinoin, vitamin A intake above 10000 IU per day or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of the initiation of treatment. Inhaled, intranasal or ocular corticosteroids are allowed if use is stable (stable use is defined as dose and frequency unchanged for at least 4 weeks prior to the initiation of treatment)

- Retinoid, cyclosporine therapy within 6 months of the initiation of treatment

- Finasteride (Propecia®, etc.), dutasteride or a similar product(s) within 12 months of the initiation of treatment

- Chemotherapy, cytotoxic agents or radiation (of the scalp) within 12 months of the initiation of treatment

- Other systemic therapy which may materially affect the subject's hair or hair growth in the opinion of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CB-03-01 solution
Investigational drug solution
Minoxidil Solution 5%
FDA approved marketed product
Placebo solution
Vehicle solution

Locations

Country Name City State
United States DermResearch, Inc. Austin Texas
United States Minnesota Clinical Study Center Fridley Minnesota
United States Therapeutics Clinical Research San Diego California

Sponsors (1)

Lead Sponsor Collaborator
Intrepid Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Target Area Hair Count (TAHC) Changes from Baseline in TAHC [in number of non-vellus hairs] using digital image analysis at Month 6. Baseline and Month 6
Primary Subject Self Assessment (Hair Growth Assessment [HGA]) The subject's evaluation of treatment benefit via the HGA questionnaires at Month 6. Scalp hair growth is compared from baseline using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3). Month 6
Secondary Change in Target Area Hair Width (TAHW) Changes from Baseline in TAHW [in µm/cm2] using digital image analysis at Month 6. Baseline and Month 6
Secondary Change in Target Area Hair Density (TAHD) Changes from Baseline in TAHD [in intensity units] using digital image analysis at Month 6. Baseline and Month 6
Secondary Subject evaluation of treatment benefit via the Hair Growth Index (HGI) and Hair Growth Satisfaction Scale (HGSS) questionnaires The subject's evaluation of treatment benefit via the HGI and HGSS questionnaires at Month 6.
HGI: Hair growth is compared from baseline by three questions on a health outcome questionnaire, which are scored using the following 7-point scale: much less (-3), moderately less (-2), slightly less (-1), the same amount (0), slightly more (1), moderately more (2), much more (3).
HGSS: Hair appearance/growth is compared from baseline by five questions, which are scored using the following 7-point scale: very dissatisfied (-3), dissatisfied (-2), somewhat dissatisfied (-1), neutral/neither satisfied nor dissatisfied (0), somewhat satisfied (1), satisfied (2), very satisfied (3).
Month 6
Secondary Investigator's Global Assessment (IGA) Compared to Baseline, the investigator will assess the subject's scalp hair growth using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3). Baseline, Month 2, 4 and 6
See also
  Status Clinical Trial Phase
Completed NCT02591355 - Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment N/A
Withdrawn NCT03852992 - Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Phase 2
Recruiting NCT06239207 - Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia Phase 2
Completed NCT04945226 - A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 Phase 1/Phase 2
Completed NCT01548066 - The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss Phase 2
Completed NCT01437163 - Treatment of Androgenetic Alopecia in Males and Females N/A
Completed NCT01226459 - Clinical Trial in Females for Female Pattern Hair Loss Phase 3
Recruiting NCT06118866 - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia Phase 2
Completed NCT06149221 - Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss N/A
Withdrawn NCT04882969 - Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia N/A
Completed NCT01231607 - Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Phase 3
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT02729415 - Point-of-Care Adipose-derived Cells for Hair Growth N/A
Not yet recruiting NCT01227031 - Pharmacogenomic Study of Androgenetic Alopecia N/A
Completed NCT00981461 - Treatment of Androgenetic Alopecia in Females, 9 Beam N/A
Completed NCT01451021 - A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Phase 2
Completed NCT00151515 - A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Phase 3
Completed NCT03694067 - Androgenetic Alopecia and the JAK-STAT Pathway
Completed NCT03689452 - The Effect of Platelet Rich Plasma on Non-scarring Alopecia N/A
Completed NCT03753113 - Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5% Phase 3